Last edition
News about "biosimilar "
Lupin and Valorum Enter into Licensing Agreement for Armlupeg in US
Under the terms of the agreement, Valorum will advance the commercialisation and distribution of Armlupeg (pegfilgrastim-unne) in the US. Lupin will be responsible for manufacturing and supply of the product and will receive an upfront licence fee and a royalty payment on net sales.
Biosimilar | 05/12/2025 | By Dineshwori
Boehringer Ingelheim Teams Up with Quallent to Expand Access to adalimumab-adbm Injection
Boehringer Ingelheim has signed a deal with Quallent Pharmaceuticals to help expand patient access to citrate-free adalimumab-adbm, Boehringer's biosimilar to Humira (adalimumab), in the US.
Biosimilar | 14/05/2024 | By Aishwarya | 655
Lupin Introduces Rymti Biosimilar Etanercept in Canada
Lupin Ltd. has developed Rymti, Lupin’s first biosimilar in Canada, through its partner Sandoz Canada (Sandoz).
Biosimilar | 06/05/2024 | By Aishwarya | 444
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy